Satvat Ali J. 4
4 · BridgeBio Pharma, Inc. · Filed Jan 28, 2021
Insider Transaction Report
Form 4
Satvat Ali J.
Director
Transactions
- Award
Stock Option (Right to Buy)
2021-01-26+39,851→ 39,851 totalExercise: $16.68Exp: 2029-06-12→ Common Stock (39,851 underlying) - Award
Stock Option (Right to Buy)
2021-01-26+39,851→ 39,851 totalExercise: $26.21Exp: 2030-05-27→ Common Stock (39,851 underlying) - Award
Stock Option (Right to Buy)
2021-01-26+79,702→ 79,702 totalExercise: $10.99Exp: 2028-07-01→ Common Stock (79,702 underlying)
Footnotes (3)
- [F1]Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the "Merger Agreement"), by and among Eidos Therapeutics, Inc. ("Eidos"), the Issuer, Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of the Issuer ("Merger Sub"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of the Issuer ("Merger Sub II"), Merger Sub was merged with and into Eidos, with Eidos continuing as the surviving corporation and immediately thereafter, Eidos was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the "Effective Time"). The option became fully vested immediately prior to the Effective Time.
- [F2](Continued from Footnote 1) At the Effective Time, each such option was cancelled, assumed by the Issuer and replaced with an option to purchase 1.85 shares of the Issuer's common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such stock option is subject to the same terms and conditions applicable to the Eidos option immediately prior to the Effective Time.
- [F3]The stock option was fully vested. At the Effective Time, each such option was cancelled, assumed by the Issuer and replaced with an option to purchase 1.85 shares of the Issuer's common stock at an exercise price per share of the Issuer's common stock equal to the exercise price per share of the Eidos option divided by 1.85. Such stock option is subject to the same terms and conditions applicable to the Eidos option immediately prior to the Effective Time.